Trial Profile
An Open-Label, Single Arm Study of MK-8808 in Patients With Advanced CD20-Positive Follicular Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Prednisolone; Vincristine
- Indications Follicular lymphoma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 24 Nov 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Feb 2014 Planned End Date changed from 1 Sep 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.